Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer's Disease in the United States. - Boustani M; Doty EG; Garrison LP Jr; Smolen LJ; Klein TM; Murphy DR; Spargo AW; Belger M; Johnston JA (Neurology and therapy, 2024)